Insider Trading July 8, 2026 08:24 PM

Omada Health CFO Steven Cook Executes $1.03M Stock Sale Under Pre-Arranged Plan

Executive divestment coincides with strong quarterly performance and analyst upgrade, though valuation metrics suggest caution.

By Ajmal Hussain
Share
Twitter Reddit Facebook LinkedIn
OMDA

Omada Health Inc. (NASDAQ:OMDA) Chief Financial Officer Steven L. Cook has sold 50,950 shares of company stock in late June, realizing approximately $1,034,616 in proceeds. The transactions were facilitated through a pre-arranged 10b5-1 trading plan established on March 14, 2026. Prior to the sale, Cook exercised stock options for the same number of shares at a cost of roughly $416,620, resulting in a net profit from the exercise-and-sale activity. Following these transactions, Cook retains direct ownership of 187,209 shares. The executive activity occurs against a backdrop of robust financial results for the first quarter of 2026, where Omada Health reported revenue of $78 million, a 42% year-over-year increase, and an earnings per share of -$0.05, which beat the consensus estimate of -$0.08. Additionally, the company recently held its 2026 Annual Meeting of Stockholders, electing Sean Duffy and Trevor Fetter as Class I Directors to serve until 2029. Market sentiment appears mixed, with Citizens raising its price target to $21 while maintaining a Market Outperform rating, although other analysis suggests the stock may be overvalued at current trading levels.

Omada Health CFO Steven Cook Executes $1.03M Stock Sale Under Pre-Arranged Plan
OMDA
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Omada Health CFO Steven Cook sold 50,950 shares for approximately $1.03 million under a pre-arranged 10b5-1 plan, having exercised options for the same shares at a lower cost.
  • The company reported strong Q1 2026 financials, with revenue increasing 42% year-over-year to $78 million and EPS of -$0.05 beating estimates.
  • Analyst sentiment is mixed, with Citizens raising its price target to $21, while other analysis suggests the stock may be overvalued at 2.5 times the 2026 revenue estimate.

Steven L. Cook, serving as the Chief Financial Officer for Omada Health, Inc. (NASDAQ:OMDA), has executed a significant divestment of company equity. In late June, Cook sold a total of 50,950 shares of the firm's common stock. The transactions generated gross proceeds of approximately $1,034,616. These sales were carried out under the parameters of a pre-arranged 10b5-1 trading plan, which was initially adopted on March 14, 2026. The use of this specific trading plan indicates that the sales were scheduled in advance rather than being reactive to immediate market conditions or private information.

The execution of these sales occurred across two distinct dates within the month. On June 26, Mr. Cook disposed of 33,000 shares. The weighted average price for this tranche was recorded at $19.8924 per share. These shares were liquidated through multiple trades, with individual execution prices varying between $19.6727 and $20.078. A subsequent sale of 17,950 shares took place on June 29 at a price of $21.0678 per share. Consequently, the overall price range for all shares sold during this period spanned from $19.8924 to $21.0678.

Crucially, the shares sold by Mr. Cook were not held prior to the transaction dates. Prior to the sales, Mr. Cook acquired the corresponding 50,950 shares through the exercise of stock options. These exercises were structured as same-day exercise-and-sale transactions. The acquisition of these shares was recorded on June 26 and June 29, with exercise prices ranging from $8.01 to $8.28 per share. The total cost associated with exercising these options amounted to approximately $416,620. This detailed sequence of events was clarified in an amended Form 4 filing, which restated the original submission to include the previously omitted exercise transactions.

Following the completion of these reported transactions, Mr. Cook's direct holdings in Omada Health common stock stand at 187,209 shares. This remaining stake provides a measure of his continued alignment with shareholder interests, despite the recent divestment.

The executive activity occurs against a backdrop of significant operational and financial developments for Omada Health. The company recently reported its financial results for the first quarter of 2026. The reported earnings per share (EPS) was -$0.05, which exceeded the forecasted EPS of -$0.08. Revenue for the quarter reached $78 million, marking a substantial 42% increase compared to the previous year. These figures highlight a trajectory of growth within the digital health and SaaS sectors, where platform businesses are increasingly demonstrating pricing power and user adoption.

Corporate governance updates also accompanied the financial disclosures. Omada Health held its 2026 Annual Meeting of Stockholders, during which Sean Duffy and Trevor Fetter were elected as Class I Directors. Both individuals are set to serve until the 2029 annual meeting, providing continuity in board oversight.

Market analysts have responded to these developments with varying perspectives. Citizens raised its price target for Omada Health to $21 from $18, while maintaining a Market Outperform rating. Analyst Constantine Davides highlighted that Omada Health recently traded at 2.5 times the firm's 2026 revenue estimate. This multiple suggests that the market is pricing in significant future growth expectations. However, contrary to the bullish stance from Citizens, other analysis indicates that the stock appears overvalued at current levels. The stock currently trades at $22.98, with a market capitalization of $1.37 billion. This valuation reflects strong momentum, with the stock recording a 49% gain over the past six months.

The divergence in analyst opinions underscores the complexity of valuing high-growth technology and healthcare companies. While revenue growth is robust, the premium valuation multiples require sustained execution to justify the current price points. Investors monitoring insider activity must weigh the executive's divestment against the company's fundamental growth metrics and the broader market sentiment toward the sector.

Risks

  • The stock appears overvalued at current levels according to some analysis, posing a risk of correction if growth expectations are not met.
  • Trading at 2.5 times the 2026 revenue estimate indicates high valuation expectations, which can be sensitive to market sentiment shifts in the technology sector.
  • Insider selling, even under a 10b5-1 plan, can signal reduced confidence or liquidity needs, potentially impacting investor perception in the digital health space.

More from Insider Trading

Warby Parker Co-CEO Blumenthal Executes $275,908 Stock Sale Under Pre-Arranged Trading Plan Jul 8, 2026 Warby Parker Co-CEO David Gilboa Executes $1.62 Million Stock Sale Under Pre-Arranged Plan Jul 8, 2026 Glaukos Corp CFO Alex Thurman Executes $1.5M Share Sale Under Pre-Planned Trading Agreement Jul 8, 2026 Natera Chairman's Strategic Share Disposition Amid Clinical Milestones Jul 8, 2026 Rivian Director Karen Boone Offloads $400,000 in Shares Under Pre-Arranged Plan Jul 8, 2026